DelveInsight’s, “HER2 Positive Gastric Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in HER2 Positive Gastric Cancer pipeline landscape. It covers the HER2 Positive Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Gastric Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the HER2 Positive Gastric Cancer Pipeline Report

• DelveInsight’s HER2 Positive Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2 Positive Gastric Cancer treatment.
• The leading companies working in the HER2 Positive Gastric Cancer Market include Pieris Pharmaceuticals, BioInvent International, Bellicum Pharmaceuticals, Mersana Therapeutics, Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Byondis, Celularity Incorporated, Triumvira Immunologies, Shanghai Miracogen Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Hengrui Therapeutics, Inc., Zymeworks Inc., Bavarian Nordic, Imugene Limited, Shanghai PerHum Therapeutics Co., Ltd., and others.
• Promising HER2 Positive Gastric Cancer Pipeline Therapies in the various stages of development include TAC01-HER2, Margetuximab, Retifanlimab, Tebotelimab, and others.
• November 2023: Memorial Sloan Kettering Cancer Center announced a study of Phase 2 clinical trials for Afatinib and Paclitaxel. The purpose of this study is to find out what effects, good or bad, the combination of standard chemotherapy agent paclitaxel with the investigational (experimental) drug afatinib that targets HER2, has on HER2-positive esophagogastric cancer that started to get bigger despite previous treatment with trastuzumab. The doctors will also study the tumor to understand why it grew while on trastuzumab treatment and to see the effects afatinib and paclitaxel has on the tumor.
• November 2023: Jazz Pharmaceuticals announced a study of Phase 3 clinical trials for Zanidatamab, Tislelizumab, Trastuzumab, and Capecitabine. This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
• November 2023: Hoffmann- La Roche announced a study of Phase 2 clinical trials for Atezolizumab, Trastuzumab, Capecitabine and Oxaliplatin. This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.

 

Request a sample and discover the recent advances in HER2 Positive Gastric Cancer Treatment Drugs @ HER2 Positive Gastric Cancer Pipeline Report

 

In the HER2 Positive Gastric Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2 Positive Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

HER2 Positive Gastric Cancer Overview

Gastric cancer is the sixth most common cancer and the third most common cause of cancer-related death in the world. Early gastric cancer has no associated symptoms; however, some patients with incidental complaints are diagnosed with early gastric cancer. Most symptoms of gastric cancer reflect advanced disease. All physical signs in gastric cancer are late events.

 

Find out more about HER2 Positive Gastric Cancer Therapeutics Assessment @ HER2 Positive Gastric Cancer Preclinical and Discovery Stage Products

 

HER2 Positive Gastric Cancer Emerging Drugs Profile

• Cinrebafusp alfa: Pieris Pharmaceuticals
• BI-1607: BioInvent International

 

HER2 Positive Gastric Cancer Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for HER2 Positive Gastric Cancer. The HER2 Positive Gastric Cancer companies which have their HER2 Positive Gastric Cancer drug candidates in the most advanced stage, i.e. phase II include, Pieris Pharmaceuticals.

 

DelveInsight’s HER2 Positive Gastric Cancer Pipeline Report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

​​​​​​HER2 Positive Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

 

HER2 Positive Gastric Cancer Pipeline Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

 

Learn more about the emerging HER2 Positive Gastric Cancer Pipeline Therapies @ HER2 Positive Gastric Cancer Clinical Trials Assessment

 

Scope of the HER2 Positive Gastric Cancer Pipeline Report

• Coverage- Global
• HER2 Positive Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2 Positive Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• HER2 Positive Gastric Cancer Companies- Pieris Pharmaceuticals, BioInvent International, Bellicum Pharmaceuticals, Mersana Therapeutics, Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Byondis, Celularity Incorporated, Triumvira Immunologies, Shanghai Miracogen Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Hengrui Therapeutics, Inc., Zymeworks Inc., Bavarian Nordic, Imugene Limited, Shanghai PerHum Therapeutics Co., Ltd., and others.
• HER2 Positive Gastric Cancer Pipeline Therapies- TAC01-HER2, Margetuximab, Retifanlimab, Tebotelimab, and others.

 

Dive deep into rich insights for new drugs for HER2 Positive Gastric Cancer Treatment, Visit @ HER2 Positive Gastric Cancer Market Drivers and Barriers, and Future Perspective

 

 

Table of Content

1. Introduction
2. Executive Summary
3. HER2 Positive Gastric Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2 Positive Gastric Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cinrebafusp alfa: Pieris Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. BI-1607: BioInvent International
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2 Positive Gastric Cancer Key Companies
21. HER2 Positive Gastric Cancer Key Products
22. HER2 Positive Gastric Cancer- Unmet Needs
23. HER2 Positive Gastric Cancer- Market Drivers and Barriers
24. HER2 Positive Gastric Cancer- Future Perspectives and Conclusion
25. HER2 Positive Gastric Cancer Analyst Views
26. HER2 Positive Gastric Cancer Key Companies
27. Appendix

 

For further information on the HER2 Positive Gastric Cancer Pipeline therapeutics, reach out to HER2 Positive Gastric Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/type-1-diabetes-market